Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
Betsi Cadwaladr University Health Board
Headquarters, Ysbyty Gwynedd, Penrhosgarnedd
Bangor
LL57 2PW
UK
Contact person: Vicky Allum
Telephone: +44 2921501263
E-mail: vicky.allum@wales.nhs.uk
NUTS: UKL
Internet address(es)
Main address: https://bcuhb.nhs.wales/
Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA88547
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Edoxaban Review Service W94038
Reference number: BCU-MSP02-Edoxaban-W94038
II.1.2) Main CPV code
85121100
II.1.3) Type of contract
Services
II.1.4) Short description
The service is to review those prescribed edoxaban in primary care with a view to changing them to a more cost effective alternative.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
4 260.00
GBP
II.2) Description
II.2.2) Additional CPV code(s)
85121100
II.2.3) Place of performance
NUTS code:
UKL
UKL11
II.2.4) Description of the procurement
Edoxaban Review Service is a service that requires a clinical review of all patients prescribed edoxaban for atrial fibrillation registered with GPs in BCUHB to assess if they are suitable for a more cost effective alternative and then change those that are.
Part 1 - Edoxaban Patient Review
Clinical review of the records of patients prescribed edoxaban.
Anyone not deemed suitable for the switch must be evidenced in the records, consider using the phrase
Edoxaban switch not clinically appropriate (no code) or,
Edoxaban contraindicated (SNOMED CT:2949391000000118) or,
Adverse reaction to edoxaban (SNOMED CT:1957181000006103).
Those deemed suitable for a switch proceed to a consultation with the patient or their representative. Consultations to switch edoxaban to generic apixaban or generic rivaroxaban can be done via telephone, virtually or face-to-face.
This must be documented in the notes, consider using the phrase
Edoxaban switch clinically appropriate (no code) or,
Edoxaban declined (SNOMED CT:1443911000000106)
Part 2 - Edoxaban Patient Review that results in a switch to generic apixaban or generic rivaroxaban
If clinically appropriate and the patient agrees to the switch to either generic rivaroxaban or generic apixaban; prescribe as indicated.
This is a new service and will run from 1st August 2026 until 31st January 2027.
This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award.
II.2.5) Award criteria
Quality criterion: most suitable provider process with regard to the key criteria
/ Weighting: 100
Cost criterion: most suitable provider process with regard to the key criteria
/ Weighting: pass
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Award of a contract without prior publication of a call for competition
Justification for selected award procedure:
The procurement falls outside the scope of application of the Directive
Explanation
‘This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 11.59pm 10th August 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR Wales'.
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2026/S 000-064486
Section V: Award of contract
Contract No: BCU-MSP02-Edoxaban-W94038
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/07/2026
V.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 1
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 0
Number of tenders received by electronic means: 0
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
MEDDYGFA VICTORIA
Victoria Road
Holyhead
LL65 1UD
UK
Telephone: +44 7780884453
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 4 260.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 11.59pm 10th August 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR Wales.
The decision makers were the Associate Director Primary Care, Medical Director Primary Care, Head of Pharmacy Primary Care, Primary Care Contracts Manager and Clinical Governance Managers. There are no noted conflict of interests.
As part of the review all basic and key criteria were included with a pass/ fail weighting for all criteria and an award being made when all criteria were met. The Health Board determined that, due to the low-risk and highly specified nature of the service, providers would be assessed against mandatory requirements aligned to the PSR key criteria. Providers demonstrating appropriate clinical governance arrangements, capacity to deliver the reviews within the service period, compliance with the DOAC LSS and acceptance of the service specification were awarded contracts. Providers failing to satisfy one or more mandatory requirements were not awarded. This provider met all criteria.
(WA Ref:168503)
VI.4) Procedures for review
VI.4.1) Review body
High Court
Royal Courts of Justice, The Strand
London
WC2A 2LL
UK
Telephone: +44 2079477501
VI.5) Date of dispatch of this notice
29/07/2026